Weight loss drugs have been available since the 1930s, but their popularity surged recently after the Food and Drug Administration (FDA) approved three GLP-1 receptor agonists for weight loss: Wegovy (semaglutide), Saxenda (liraglutide), and Ozempic (tirzepatide)
Ozempic is a synthetic version of GLP-1, used to aid in weight loss by reducing appetite, slowing stomach emptying, and increasing fullness
Parallel efforts are exploring new indications, including neurodegenerative and substance use disorders, metabolic liver disease, arthritis, type 1 diabetes and inflammatory bowel disease
Recent data from the Central Drugs Standard Control Organization notes that the approval process for new drugs can take between 12 to 24 months, leading to delays in product launches
While Semaglutide revolutionized the market, the addition of the GIP receptor in Tirzepatide showed that multi-pathway targeting was more effective
LEADER Steering Committee